Insulin-resistant diabetes during growth hormone therapy in a child with SHORT syndrome.
We report the case of a 13-year-old boy with SHORT syndrome, including lipoatrophy and insulin resistance, who developed diabetes mellitus while receiving growth hormone therapy. The diabetes persisted after cessation of exogenous growth hormone but oral hypoglycaemic therapy was successful and could be discontinued eight months later.
Verge
C F
CF
Ray Williams Institute of Paediatric Endocrinology, Royal Alexandra Hospital for Children, Sydney, Australia.
Donaghue
K C
KC
Williams
P F
PF
Cowell
C T
CT
Silink
M
M
D000015:Abnormalities, Multiple / Q000188:drug therapy*; D000848:Anodontia / Q000150:complications*; D001786:Blood Glucose / Q000032:analysis; D002648:Child; D003923:Diabetes Mellitus, Lipoatrophic / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy; D005124:Eye Abnormalities / Q000150:complications*; D005147:Facial Bones / Q000002:abnormalities*; D006130:Growth Disorders / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D013006:Growth Hormone / Q000009:adverse effects*; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D013577:Syndrome
D001786:Blood Glucose; D007328:Insulin; D013006:Growth Hormone; D008687:Metformin